Efficacy of IL12/23 blockade expands our therapeutic targets and challenges the old dogma in ulcerative colitis

Sands et al. expand the therapeutic potential of anti-IL-12/IL-23 blockade in IBD, by demonstrating a clear clinical benefit of ustekinumab as induction and maintenance therapy for ulcerative colitis (UC). The UNIFI trial had a double-blind, placebo-control design and consisted of an 8-week induction and a 44-week randomized-withdrawal maintenance trial. Patients with active, moderate-to-severe UC (total Mayo score of 6-12 with endoscopic subscore of ≥2 via central reading) were recruited from 244 centers worldwide.

Source link

Related posts

Single-dose aspirin fails to improve FIT results


VIDEO: Social networking crucial to ‘cultivate the next generation’


First Human Case of Rat Strain of Hepatitis E Seen in Hong Kong


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy